FluxMPS™ MEM, Low Glucose with Earle's Salts

FluxMPS™ MEM, Low Glucose with Earle's Salts

FluxMPS™ MEM, Low Glucose with Earle's Salts (DCP-MEM-N1X) is an MPS-grade, quadruple-stage ultra-filtered Minimum Essential Medium formulated for organ-on-a-chip (OoC), microphysiological system (MPS), and microfluidic channel applications where conventional 0.22 µm-filtered media falls short. Manufactured under ISO 13485:2016-certified conditions and filled in an ISO Class 5 (Class 100) aseptic environment, this ultra-clean, sub-mycoplasma-polished medium delivers approximately 5× fewer particles than standard-filtered media — making it microchannel-safe and biosensor-compatible from the first priming flush.

• Quadruple-stage nano-filtration: 0.1 µm × 2 + 0.04 µm × 2, sequentially; mycoplasma-barrier confirmed
• Final 0.04 µm (40 nm) polish — the only MEM ready-to-use at this purity level; USP <788> particulate-compliant
• Endotoxin ≤ 1 EU/mL (USP <85> BET); 14-day USP <71> sterility verified; no bacterial or fungal growth observed
• Low glucose (1.0 g/L D-Glucose), L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Earle's Salts — core formulation pre-validated for metabolic studies
• Ultrapure Type 1 water (18.2 MΩ·cm) as solvent; USP <85> water-quality-equivalent baseline
• ISO Class 5 (Class 100) aseptic fill & finish; ISO 13485:2016 QMS throughout
• Custom pH, glucose concentration, salts, HEPES, and nutrient composition available on request — contact support@diagnocine.com

Engineered where standard media fails

Conventional 0.22 µm-filtered media was designed for flask culture — not the nanoscale geometries of organ-on-a-chip devices, biosensor arrays, or perfusion bioreactors. Sub-visible particulates (2–20 µm), residual mycoplasma-sized debris, and micro-aggregates block microchannels, coat optical surfaces, corrupt electrochemical signals, and introduce batch-to-batch variance that poisons reproducibility. FluxMPS™ eliminates these failure modes through a purpose-built, four-barrier filtration architecture that reaches 0.04 µm — a class-leading purity no other ready-to-use MEM currently matches.^[1,2]

Quadruple-stage filtration system

FluxMPS™ MEM is the only ready-to-use MEM filtered to a final 0.04 µm pore size through a four-stage sequential barrier — a sterilization depth not achievable with conventional 0.22 µm single-pass methods. Each stage performs a distinct function; together they deliver sub-mycoplasma polishing, 14-day USP <71> sterility, and USP <63>-equivalent mycoplasma assurance.

1. 1

   0.1 µm Pre-filtration I — Large Particulate & Aggregate Removal

   First 0.1 µm pass captures large particulates, media aggregates, and cell-debris-sized contaminants, significantly extending the effective life of the downstream fine-filter stages and protecting pore integrity.

2. 2

   0.04 µm Pre-filtration II — Fine Particulates, Bacteria & Mycoplasma Retention

   The first 0.04 µm membrane intercepts bacteria, fine particulates, and mycoplasma-sized particles (smallest known mycoplasma ≈ 0.2 µm) before the final sterile barrier, providing redundant bioburden reduction.

3. 3

   0.1 µm Sterile-filtration I — Second-Pass Redundancy

   Second 0.1 µm sterile-filtration pass provides redundant bioburden removal, ensuring any particles that passed Stage 1 are captured before the critical final polish, per 21 CFR Part 820 cGMP-aligned redundancy principles.

4. 4

   0.04 µm Sterile-filtration II — Final Polish & ISO Class 5 Aseptic Fill

   Ultimate 0.04 µm final-polish membrane in an ISO Class 5 (Class 100) cleanroom delivers the ultra-low-particulate, mycoplasma-controlled medium directly into sterile containers — no post-fill processing required.

Validated across advanced in-vitro platforms

FluxMPS™ MEM, Low Glucose with Earle's Salts is designed for demanding MPS, organ-on-a-chip, and precision in-vitro platforms where media purity directly determines experimental success. Its low-glucose formulation makes it particularly suited for metabolic research, cancer biology, and any application requiring user-defined carbon-source control.^[3,4]

Automated Bioreactors & Robotics

For automated perfusion bioreactors and robotic liquid-handling platforms, an optional 10 nm (0.01 µm) ultra-filtered variant is available, designed to eliminate nano-particulate fouling of precision valves, sensors, and microfluidic tubing over extended continuous runs.

• Total Particulate Exclusion — nano-filtered variant removes particles down to 10 nm, protecting pressure sensors and proportional valves from drift and occlusion
• Valve & Sensor Protection — ultra-low particulate count prevents wear on elastomeric micro-valves and pin-point electrode surfaces during multi-week automated perfusion runs
• Extended Perfusion Stability — consistent ionic strength, osmolality, and particle profile over the full 12-month shelf life supports automated scheduling without lot-to-lot re-optimization

Inquiry Required: The 0.01 µm (10 nm) ultra-filtered grade is produced on a make-to-order basis. Contact support@diagnocine.com to request the 0.01 µm grade and discuss throughput, format, and lead-time requirements.

Quality-controlled parameters — per-lot release

All parameters below are measured on every production lot at DiagnoCine's R&D and Quality Testing Center in Totowa, NJ. Results are documented in the lot-specific Certificate of Analysis (CoA).

Full composition (mg/L)

Complete ingredient listing per lot-release specification. All values are per liter of 1X final medium. Concentrations reflect higher amino acid density vs. Basal Medium Eagle (BME) baseline — manufactured under ISO 13485:2016 QMS with per-lot release CoA available on request.

Manufacturing standards & compliance

FluxMPS™ MEM is manufactured under ISO 13485:2016-certified Quality Management Systems at DiagnoCine's supplier facilities (CE-approved), with all final packaging, quality assurance, and testing performed at DiagnoCine's R&D and Quality Testing Center in Totowa, New Jersey, USA.

How DCP-MEM-N1X compares

FluxMPS™ MEM (DCP-MEM-N1X) versus conventional 0.22 µm-filtered MEM and a standard single-pass 0.1 µm MEM alternative. Key differentiators are highlighted.

Frequently asked questions

Common questions about FluxMPS™ MEM, Low Glucose with Earle's Salts (DCP-MEM-N1X).

Supporting literature

Peer-reviewed publications supporting the scientific basis for MPS-grade cell culture media, quadruple-stage filtration, organ-on-a-chip applications with MEM, metabolic research in low-glucose media, and mycoplasma prevention strategies.

1. Huh D, Matthews BD, Mammoto A, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–1668.doi:10.1126/science.1188302
2. Zhang B, Radisic M. Organ-on-a-chip devices advance to market. Lab Chip. 2017;17(14):2395–2420.doi:10.1039/C7LC00248C
3. Maoz BM, Herland A, FitzGerald EA, et al. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic coupling of endothelial and neuronal cells. Nat Biotechnol. 2018;36(9):865–874.doi:10.1038/nbt.4226
4. Eagle H. Amino acid metabolism in mammalian cell cultures. Science. 1959;130(3373):432–437.doi:10.1126/science.130.3373.432
5. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.doi:10.1126/science.1160809
6. Jang KJ, Mehr AP, Hamilton GA, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol (Camb). 2013;5(9):1119–1129.doi:10.1039/c3ib40049b
7. Langford DT, Waldron JA. Mycoplasma contamination of cell cultures: a persistent problem. J Appl Bacteriol. 1985;59(5):483–491.doi:10.1111/j.1365-2672.1985.tb03349.x
8. Ewart L, Apostolou A, Briggs SA, et al. Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Commun Med. 2022;2(1):154.doi:10.1038/s43856-022-00209-1
9. Bein A, Shin W, Jalili-Firoozinezhad S, et al. Microfluidic organ-on-a-chip models of human intestine. Cell Mol Gastroenterol Hepatol. 2018;5(4):659–668.doi:10.1016/j.jcmgh.2017.12.010
10. Bhise NS, Ribas J, Manoharan V, et al. Organ-on-a-chip platforms for studying drug delivery systems. J Control Release. 2014;190:82–93.doi:10.1016/j.jconrel.2014.05.004